Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2020

18.02.2020 | Epidemiology

The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer

verfasst von: Lili Chen, Fangmeng Fu, Meng Huang, Jinxing Lv, Wenzhe Zhang, Chuan Wang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

BRCA1/2 mutations represent a high risk of breast cancer and are related to early-onset breast cancer. However, few studies have reported the relationship between BRCA1/2 mutations and their clinical characteristics in early-onset breast cancers. This study is the first article that characterizes the risk factor profiles in Chinese patients selected by the age of onset (≤ 40 years old). We found some differences in the prevalence of germline BRCA1/2 mutations between Asian and Western countries.

Methods

A total of 1371 consecutive unselected Chinese early-onset breast cancer patients were enrolled from the Fujian Medical University Union Hospital, China, and screened for germline BRCA1/2 mutations. Full-exome sequencing in next-generation sequencing technology was performed in all patients to examine BRCA1/2 mutations.

Results

In our study, 25 (1.8%) and 61 (4.4%) patients were identified with BRCA1 and BRCA2 mutations, respectively, among the unselected early-onset breast cancer patients. BRCA1 mutations were associated with pregnancies (p = 0.026), and BRCA1 carriers had a higher likelihood of being HR positive (p < 0.001), HER2 negative (p < 0.001), or high grade (p = 0.002) than noncarriers. Among BRCA2 mutations, the age of onset was younger in carriers than in noncarriers (p = 0.017), and BRCA2 carriers were more likely to have lymph node metastasis (p = 0.004). HR-positive or HER2-negative patients were likely to be positive for BRCA2 mutations (p < 0.001). Overall, 14 BRCA1 mutations and 8 BRCA2 mutations were first reported in our study

Conclusion

This study provided some information about the spectrum of BRCA1/2 mutations and characterized the risk factors for early-onset breast cancer in China.
Literatur
1.
Zurück zum Zitat Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(1):S2–S8PubMedPubMedCentral Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(1):S2–S8PubMedPubMedCentral
3.
Zurück zum Zitat Radecka B, Litwiniuk M et al (2016) Breast cancer in young women. Ginekol Pol 87(9):659–663CrossRefPubMed Radecka B, Litwiniuk M et al (2016) Breast cancer in young women. Ginekol Pol 87(9):659–663CrossRefPubMed
4.
Zurück zum Zitat Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32(5):431–437CrossRefPubMed Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ et al (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32(5):431–437CrossRefPubMed
5.
Zurück zum Zitat Rosenberg Shoshana M, Kathryn J, Ruddy Rulla M et al (2016) BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol 2(6):730–736CrossRefPubMedPubMedCentral Rosenberg Shoshana M, Kathryn J, Ruddy Rulla M et al (2016) BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol 2(6):730–736CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Chuang C, Sun S, Jing-Ping Y, Yao-Huai W, Yi T, Feng Y et al (2016) Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast 30:208–213CrossRef Chuang C, Sun S, Jing-Ping Y, Yao-Huai W, Yi T, Feng Y et al (2016) Characteristics of breast cancer in Central China, literature review and comparison with USA. Breast 30:208–213CrossRef
7.
Zurück zum Zitat Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330CrossRefPubMed Anders CK, Hsu DS, Broadwater G et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324–3330CrossRefPubMed
8.
Zurück zum Zitat Soley B, Banu A (2016) BRCA mutation genetic testing implications in the United States. Breast 31:224–232 Soley B, Banu A (2016) BRCA mutation genetic testing implications in the United States. Breast 31:224–232
10.
Zurück zum Zitat Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple negative breast cancer. BMC Cancer 9:1–5CrossRef Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple negative breast cancer. BMC Cancer 9:1–5CrossRef
11.
Zurück zum Zitat Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308CrossRefPubMedCentral Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308CrossRefPubMedCentral
12.
Zurück zum Zitat Yang XR, Devi BCR, Sung H et al (2017) Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak. Breast Cancer Res Treat 165(3):687–697CrossRefPubMedPubMedCentral Yang XR, Devi BCR, Sung H et al (2017) Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak. Breast Cancer Res Treat 165(3):687–697CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):115–123CrossRefPubMed Rennert G, Bisland-Naggan S, Barnett-Griness O et al (2007) Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):115–123CrossRefPubMed
14.
Zurück zum Zitat Verhoog LC, Brekelmans CT, Seynaeve C et al (1998) Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351:316–321CrossRefPubMed Verhoog LC, Brekelmans CT, Seynaeve C et al (1998) Survival and tumour characteristics of breast cancer patients with germline mutations of BRCA1. Lancet 351:316–321CrossRefPubMed
15.
Zurück zum Zitat Huzarski T, Byrski T, Gronwald J et al (2013) Ten year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191–3196CrossRefPubMed Huzarski T, Byrski T, Gronwald J et al (2013) Ten year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191–3196CrossRefPubMed
16.
Zurück zum Zitat Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119:13–24CrossRefPubMed Bordeleau L, Panchal S, Goodwin P (2010) Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 119:13–24CrossRefPubMed
17.
Zurück zum Zitat Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324CrossRefPubMed Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318–2324CrossRefPubMed
18.
Zurück zum Zitat Jie S, Hua M, Lu Y, Meng L, Xie Y et al (2017) Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res 23(20):6113–6119CrossRef Jie S, Hua M, Lu Y, Meng L, Xie Y et al (2017) Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res 23(20):6113–6119CrossRef
19.
Zurück zum Zitat Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Shao ZM (2017) The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2991 patients and 1043 controls by next-generation sequencing. Int J Cancer 141(1):129–142CrossRefPubMed Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Shao ZM (2017) The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: screening of 2991 patients and 1043 controls by next-generation sequencing. Int J Cancer 141(1):129–142CrossRefPubMed
20.
Zurück zum Zitat Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL (2015) The CIMBA consortium, association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361CrossRefPubMedPubMedCentral Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL (2015) The CIMBA consortium, association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, Pierzchalski P (2016) Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovariancancer patients in Southern Poland. Hered Cancer Clin Pract 14:5CrossRefPubMedPubMedCentral Wojcik P, Jasiowka M, Strycharz E, Sobol M, Hodorowicz-Zaniewska D, Skotnicki P, Pierzchalski P (2016) Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovariancancer patients in Southern Poland. Hered Cancer Clin Pract 14:5CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Caux-Moncoutier V, Pages-Berhouet S, Michaux D, Asselain B, Houdayer C (2009) Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 17(11):1471–1480CrossRefPubMedPubMedCentral Caux-Moncoutier V, Pages-Berhouet S, Michaux D, Asselain B, Houdayer C (2009) Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 17(11):1471–1480CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Kim YC, Zhao L, Zhang H, Huang Y, Cui J, Xiao F, Downs B, Wang SM (2016) Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients. Oncotarget 7(8):9600–9612CrossRefPubMedPubMedCentral Kim YC, Zhao L, Zhang H, Huang Y, Cui J, Xiao F, Downs B, Wang SM (2016) Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients. Oncotarget 7(8):9600–9612CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Yang X, Wu J, Lu J, Liu G, Di G, Chen C, Sun M, Hu Z (2015) Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS ONE 10(4):30125571 Yang X, Wu J, Lu J, Liu G, Di G, Chen C, Sun M, Hu Z (2015) Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS ONE 10(4):30125571
25.
Zurück zum Zitat Li WF, Hu Z, Rao NY, Song CG, Zhang B, Shao ZM (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110(1):99–109CrossRefPubMed Li WF, Hu Z, Rao NY, Song CG, Zhang B, Shao ZM (2008) The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. Breast Cancer Res Treat 110(1):99–109CrossRefPubMed
26.
Zurück zum Zitat Suter NM, Ray RM, Hu YW, Lin MG, Porter P (2004) BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epedemiol Biomarkers Prev 13(2):181–189CrossRef Suter NM, Ray RM, Hu YW, Lin MG, Porter P (2004) BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epedemiol Biomarkers Prev 13(2):181–189CrossRef
27.
Zurück zum Zitat Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z (2005) A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam Cancer 4(2):89–96CrossRefPubMed Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z (2005) A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques. Fam Cancer 4(2):89–96CrossRefPubMed
28.
Zurück zum Zitat Zhang J, Sun J, Chen J, Yao L, Ouyang T, Li J, Xie Y (2016) Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. Breast Cancer Res Treat 158(3):455–462CrossRefPubMed Zhang J, Sun J, Chen J, Yao L, Ouyang T, Li J, Xie Y (2016) Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer. Breast Cancer Res Treat 158(3):455–462CrossRefPubMed
29.
Zurück zum Zitat Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP (2012) Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort(GENEPSO). Breast Cancer Res 14(4):R99CrossRefPubMedPubMedCentral Lecarpentier J, Noguès C, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Fricker JP (2012) Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort(GENEPSO). Breast Cancer Res 14(4):R99CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C et al (2016) Prevalence of BRCA1/2 germline mutations in 21401 families with breast and ovarian cancer. J Med Genet 53:465–471CrossRefPubMed Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, Zarghooni V, Herold N, Ditsch N, Kiechle M, Braun M, Fischer C et al (2016) Prevalence of BRCA1/2 germline mutations in 21401 families with breast and ovarian cancer. J Med Genet 53:465–471CrossRefPubMed
31.
Zurück zum Zitat Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949CrossRefPubMed Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR (1999) Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91:943–949CrossRefPubMed
32.
Zurück zum Zitat Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospectivecohort study. Lancet Oncol 19(2):169–180CrossRefPubMedPubMedCentral Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S (2018) Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospectivecohort study. Lancet Oncol 19(2):169–180CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS (2014) Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 23(6):770–774CrossRefPubMed Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS (2014) Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. Breast 23(6):770–774CrossRefPubMed
34.
Zurück zum Zitat Brown KL, Hutchison R, Zinberg E, McGovern MM (2005) Referral and experience with genetic testing among women with early onset breast cancer. Genet Test 9(4):301–305CrossRefPubMed Brown KL, Hutchison R, Zinberg E, McGovern MM (2005) Referral and experience with genetic testing among women with early onset breast cancer. Genet Test 9(4):301–305CrossRefPubMed
35.
Zurück zum Zitat Ruddy KJ, Gelber S, Shin J, Garber JE (2010) Genetic testing in young women with breast cancer: results from a web-based survey. Ann Oncol. 21(4):741–747CrossRefPubMed Ruddy KJ, Gelber S, Shin J, Garber JE (2010) Genetic testing in young women with breast cancer: results from a web-based survey. Ann Oncol. 21(4):741–747CrossRefPubMed
36.
Zurück zum Zitat Peters N, Domchek SM, Rose A, Polis R, Stopfer J, Armstrong K (2005) Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test 9(1):48–53CrossRefPubMed Peters N, Domchek SM, Rose A, Polis R, Stopfer J, Armstrong K (2005) Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer. Genet Test 9(1):48–53CrossRefPubMed
37.
Zurück zum Zitat Yao L, Sun J, Zhang J, He Y, Ouyang T, Xie Y (2016) Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat 6(3):441–445CrossRef Yao L, Sun J, Zhang J, He Y, Ouyang T, Xie Y (2016) Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. Breast Cancer Res Treat 6(3):441–445CrossRef
38.
Zurück zum Zitat Moller P, Evans DG, Reis MM et al (2007) Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 121:1017–1020CrossRefPubMed Moller P, Evans DG, Reis MM et al (2007) Surveillance for familial breast cancer: differences in outcome according to BRCA mutation status. Int J Cancer 121:1017–1020CrossRefPubMed
39.
Zurück zum Zitat (c)National Comprehensive Cancer Network, Inc., 2015. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for breast and/or ovarian cancer genetic assessment V.1.2019. National Comprehensive Cancer Network®, NCCN®, NCCN Guidelines®, and all other NCCN Content are Trademarks Owned by the National Comprehensive Cancer Network, Inc. (c)National Comprehensive Cancer Network, Inc., 2015. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for breast and/or ovarian cancer genetic assessment V.1.2019. National Comprehensive Cancer Network®, NCCN®, NCCN Guidelines®, and all other NCCN Content are Trademarks Owned by the National Comprehensive Cancer Network, Inc.
40.
Zurück zum Zitat Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90(15):1138–1145CrossRefPubMed Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90(15):1138–1145CrossRefPubMed
41.
Zurück zum Zitat Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18(21):107S–112SPubMed Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18(21):107S–112SPubMed
42.
43.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109(9):1721–1728CrossRefPubMed Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109(9):1721–1728CrossRefPubMed
44.
Zurück zum Zitat Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490CrossRefPubMed Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490CrossRefPubMed
45.
Zurück zum Zitat Gonzalez-Angulo AM, Broglio K, Kau SW et al (2005) Women age ≤ 35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466–2472CrossRefPubMed Gonzalez-Angulo AM, Broglio K, Kau SW et al (2005) Women age ≤ 35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466–2472CrossRefPubMed
46.
Zurück zum Zitat Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T (2002) Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int J Cancer 98(4):604–608CrossRefPubMed Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T (2002) Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int J Cancer 98(4):604–608CrossRefPubMed
Metadaten
Titel
The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer
verfasst von
Lili Chen
Fangmeng Fu
Meng Huang
Jinxing Lv
Wenzhe Zhang
Chuan Wang
Publikationsdatum
18.02.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05573-x

Weitere Artikel der Ausgabe 3/2020

Breast Cancer Research and Treatment 3/2020 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.